Antengene to participate in Th


CICC Healthcare Industry Forum 2022: May 9e at 12e

BTIG Virtual China Biotech Day: June 1st

Citi’s 3rd Pan-Asian Regional Investor Conference 2022: June 8e at June 10e

SHANGHAI and HONG KONG, May 5, 2022 /PRNewswire/ — Antengene Corporation Limited (“Antenna” SEHK: 6996.HK), a leading innovative and commercial global biopharmaceutical company dedicated to the discovery, development and commercialization of first-in-class and/or first-in-class therapeutics in hematology and oncology, announced today that the Company will participate virtually in three upcoming investor conferences.

CICC Healthcare Industry Forum 2022

Date of the meeting:

May 9e at 12e (biotechs & pharmaceuticals)

Event type:

Presentation of the virtual company by Dr. Jay Mei, Founder, President and CEO of Antengene

1×1 meetings

Meeting setup:

Please contact your CICC representative to arrange a meeting

BTIG Virtual China Biotech Day

Date of the meeting:

June 1st

Event type:

Panel discussions, fireside chat and 1×1 meetings

Meeting setup:

To listen to the live panel discussions and fireside chats, please
contact your BTIG representative with interest. You can also
contact your BTIG representative to arrange a meeting.

Citi’s 3rd Pan Asian Regional Investor Conference 2022

Date of the meeting:

June 8e to June 10e

Event type:

Virtual 1×1 / group meetings

Meeting setup:

Please contact your Citi representative to organize a meeting

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading R&D-driven global biopharmaceutical company focused on first-in-class/best-in-class innovative therapeutic drugs for cancer and other diseases potentially fatal. . Driven by his vision of “Treating patients across borders”, Antengene aims to provide the most advanced cancer drugs to patients in the Asia-Pacific region and around the world. Since beginning operations in 2017, Antengene has obtained 23 Investigational New Drug (IND) approvals in the United States and Asiasubmitted 6 new drug applications (NDAs) in several Asia Pacific markets, with NDA for selinexor/ATG-010/XPOVIO® in China, South Korea, Singapore and Australia approved. Leveraging partnerships as well as in-house drug discovery, Antengene has built a broad and expanding pipeline of 15 clinical and preclinical assets. Antengene holds worldwide rights to 10 programs and Asia Pacific rights, including Greater China region, on 5 programs.

Forward-looking statements

Forward-looking statements made in this article relate only to events or information as of the date the statements are made in this article. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unforeseen events. events. You should read this article in its entirety and be aware that our actual future results or performance may differ materially from what we expect. In this article, statements or references to our intentions or those of any of our directors or our company are made as of the date of this article. Each of these intentions may change in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statements, see the section entitled “Risk Factors” in our periodic reports filed with the Hong Kong Stock Exchange and other risks and uncertainties described in the company’s annual report for the end of the year December 31, 2021and subsequent filings with the Hong Kong Stock Exchange.

For more information please contact:

Investor contacts:
Donald Lung
E-mail: [email protected]
Mobile: +86 18420672158

PR contacts:
Qian Stone
E-mail: [email protected]
Mobile: +86 13062747000

favicon.png?sn=CN47701&sd=2022-05-05 View original content to download multimedia:

SOURCEAntengene Corporation Limited


About Author

Comments are closed.